For what it is worth I went back and had a look at the Strategy update at the end of 2016 and the reformulation of into powder is part of the Q1 milestones to prepare for the human trials. So IMO that it is underway is a good thing as it is in line with their strategy.
Ann: Appendix 4C - Quarterly Report & Company Update - March 2017, page-24
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $89.00M | |||
| Open | High | Low | Value | Volume |
| 19.5¢ | 20.0¢ | 19.5¢ | $101.0K | 508.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 420397 | 19.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 8821 | 1 |
View Market Depth
| Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
| PAA (ASX) Chart |